Cresud Sociedad Anónima Comercial Inmobiliaria Financiera y Agropecuaria Valuation

Q: What is the Fair Price of CD8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CD8 (€10.5) is trading above our estimate of [[fair value]] (€6.95)

Is CD8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CD8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CD8 (€10.5) is trading above our estimate of fair value (€6.95)

Significantly Below Fair Value: CD8 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CD8?

Key metric: As CD8 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CD8. This is calculated by dividing CD8's market cap by their current revenue.
What is CD8's PS Ratio?
PS Ratio	1x
Sales	AR$729.23b
Market Cap	AR$754.79b

CD8 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.2x
Enterprise Value/EBITDA	16.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CD8's PS Ratio compare to its peers?

The above table shows the PS ratio for CD8 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1x
KWS KWS SAAT SE KGaA	1.1x	4.9%	€2.0b
OEL ADM Hamburg	0.4x	n/a	€169.2m
GTK Tonkens Agrar	0.6x	n/a	€12.3m
SSH Südwestdeutsche Salzwerke	1.8x	n/a	€630.5m
CD8 Cresud Sociedad Anónima Comercial Inmobiliaria Financiera y Agropecuaria	1x	n/a	€754.8b

Price-To-Sales vs Peers: CD8 is expensive based on its Price-To-Sales Ratio (1x) compared to the peer average (1x).

Price to Sales Ratio vs Industry

How does CD8's PS Ratio compare vs other companies in the European Food Industry?

35 Companies	Price / Sales	Estimated Growth	Market Cap

35 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: CD8 is expensive based on its Price-To-Sales Ratio (1x) compared to the European Food industry average (0.7x).

Price to Sales Ratio vs Fair Ratio

What is CD8's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CD8 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CD8's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Olvi Oyj

€585.8m

A beverage company, manufactures and sells alcoholic and non-alcoholic beverages in Finland, Estonia, Latvia, Lithuania, Denmark, and Belarus.

OVI

€28.75

0.9%

-1.7%

Thai Beverage

S$13.2b

Produces and distributes alcoholic and non-alcoholic beverages, and food products worldwide.

T6W

S$0.36

2.6%

1.9%

Anheuser-Busch InBev

€103.7b

Produces, distributes, exports, markets, and sells beer and beverages.

1NBA

€52.50

-1.3%

-8.7%